Drug Profile


Alternative Names: CaCP 29; IFX-1

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beijing Mabworks Biotech; InflaRx
  • Developer InflaRx
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5a inhibitors; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa; Sepsis; Systemic inflammatory response syndrome
  • Phase I Inflammation

Most Recent Events

  • 07 Sep 2017 Top-line adverse events and efficacy data from a phase IIa trial in Hidradenitis suppurativa released by InflaRx
  • 07 Sep 2017 InflaRx plans a phase IIb trial in Hidradenitis suppurativa
  • 01 Jul 2017 InflaRx completes a phase II trial in Hidradenitis suppurativa in Greece (IV) (NCT03001622)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top